Trial Profile
A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients With Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Epirubicin (Primary)
- Indications Haemangiosarcoma; Leiomyosarcoma; Osteosarcoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors NanoCarrier
- 01 Oct 2022 Results assessing the activity of NC-6300 in angiosarcoma, an expansion cohort, published in the Oncologist.
- 08 Jun 2021 Results of an expansion cohort (N=10, 2-cutaneous and 8-non-cutaneous) analysis assessing the anti-tumor activity of NC-6300 in angiosarcoma presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 12 Oct 2020 Status changed from recruiting to active, no longer recruiting, according to a NanoCarrier media release.